ProShares Bitcoin ETF vs IDEXX Laboratories, Inc. — how do they compare? ProShares Bitcoin ETF trades at $8.57, while IDEXX Laboratories, Inc. trades at $572.06 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is trading nearer its 52-week high, ProShares Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| BITO | IDXX | |
|---|---|---|
Sector | Crypto-linked | Health |
52-Week High | $22.27 | $766.68 |
52-Week Low | $7.98 | $526.44 |
Market Cap | — | $46.22B |
Enterprise Value | — | $47.12B |
Signals from Pluang's Aura AI — not financial advice
BITO trades at $8.64 with no recent price movement, showing technical bearish signals from moving averages while oscillators remain neutral. The ETF faces headwinds as recent analysis highlights underperformance compared to spot Bitcoin ETFs, with Seeking Alpha maintaining a Sell rating for retail investors. Dividend distributions of $0.01 per share provide modest income but haven't offset significant price declines over the past year.
The outlook remains challenging with institutional sentiment turning cautious amid crypto market volatility. Key risks include high fee structures, competitive pressure from newer spot Bitcoin ETFs, and correlation breakdowns with traditional risk assets. Analyst consensus leans bearish given the fund's structural disadvantages and ongoing crypto winter conditions.
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Trailing returns across standard periods
Latest headlines on both assets
BITO offers exposure to Bitcoin returns primarily through Bitcoin futures contracts. It provides a regulated way for investors to trade Bitcoin performance within a traditional brokerage account without direct ownership.
Read more on BITO →Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →